BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data
June 18, 2015 10:03 AM EDTCanaccord Genuity reiterates a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $150.00 (from $115.00), following positive BMN-111 data. Analyst Adam Walsh increased the probability of success to 70%, from 50%, based on the strong P2 data.
Walsh commented, "We view the... More
BioMarin's (BMRN) Price Target Raised to $156 at Deutsche Bank
June 18, 2015 8:19 AM EDTDeutsche Bank maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $156.00 (from $140.00). The change follows positive phase 2 BMN-111 data in achondroplasia.
Analyst Robyn Karnauskas said, "BioMarins achondroplasia drug, BMN-111 (now called vosoritide) worked in phase 2, showing a 50% improvement in mean annualized growth velocity of... More
BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 Update
June 18, 2015 7:02 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $147.00 (from $123.00) following data from the long awaited P2 trial of BMN111 (vosoritide) in children with achondroplasia.
Schimmer commented, "Our... More
BioMarin (BMRN) PT Raised to $143 at Leerink Partners as BMN-111 Meets Primary Endpoint
June 18, 2015 6:28 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $143.00 (from $136.00) reported positive top-line results for the BMN-111 (vosoritide) Ph II trial in Achondroplasia (ACH), meeting the primary endpoint with a 50% increase in annualized... More
BioMarin Pharma (BMRN) Issues Positive Update from BMN 111 Phase 2 Proof-of-Concept, Dose Finding Study
June 17, 2015 4:05 PM EDTBioMarin Pharma (NASDAQ: BMRN) announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia. Achondroplasia is the most common form of human dwarfism. Vosoritide has Orphan designation in both the United States and Europe.
Phase 2 Results and Safety Summary of First Six Months
Data from the 26 children participating in the Phase 2 study demonstrated a favorable safety profile and efficacy at the 15 micrograms/kilogram/daily dose. The 10 children in Cohort 3 treated with 15 micrograms per kilogram per... More
